Atara Biotherapeutics (NASDAQ:ATRA) disclosed that its President and CEO, AnhCo Nguyen, sold 6,094 shares of common stock on November 16, 2026, generating proceeds of $39,368. The transaction was not a discretionary trade but rather a sale-to-cover move designed to meet tax withholding obligations tied to the vesting of previously granted restricted stock units.
The shares were disposed of automatically under a pre-arranged provision, with a weighted average price of $6.4602. That figure reflects the average price of all shares sold by a broker on November 16 and November 17, 2026, on behalf of a group of the issuer's employees to cover their withholding tax liability. After the sale, Nguyen directly holds 126,681 shares of Atara common stock.
The disclosure arrives during a difficult stretch for the biotech company. According to InvestingPro data, ATRA shares have lost roughly 15% over the past week and are trading at $6.77. Year-to-date, the stock has declined 63%. Despite the sharp pullback, analysts maintain price targets ranging from $10 to $18 per share.
InvestingPro offers 5 additional exclusive tips about ATRA's financial health and market position.